

Final Agenda

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

Tuesday, April 15, 2025

8:00 Welcome & Introductions

Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:15 Mpox Vaccine

Introduction

Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds
EtR for JYNNEOS in outbreaks and due to the 2022 global outbreak

Dr. Faisal Minhaj (CDC/NCEZID)
Dr. Buddy Creech (Vanderbilt University)
Dr. Faisal Minhaj (CDC/NCEZID)
Dr. Grace Marx (CDC/NCEZID)

9:55 Lyme Disease Vaccine

10:00 Influenza Vaccines

Introduction

Influenza vaccine effectiveness update

Dr. Jamie Loehr (ACIP, WG Chair)
Dr. Aaron Frutos (CDC/NCIRD)
Dr. Sophie Zhu (California DPH and CDC/PHIC), Dr.
Joshua Quint (California DPH)
Dr. Allyn Bandell (AstraZeneca)

FluMist self/caregiver administration

11:15 Break

11:30 COVID-19 Vaccines

Introduction

Moderna mRNA-1283 COVID-19 vaccine

Epidemiology and risk factors for COVID-19 hospitalizations

Vaccine effectiveness update

Workgroup considerations for use of 2025-2026 COVID-19 vaccines

Dr. Robert Schechter (ACIP, WG Chair)
Dr. Bishoy Rizkalla (Moderna)
Dr. Fiona Havers (CDC/NCIRD)
Dr. Ruth Link-Gelles (CDC/NCIRD)
Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)

1:30 Pneumococcal Vaccines

Workgroup Next Steps and Proposed Work Plan

Dr. Miwako Kobayashi (CDC/NCIRD)

1:45 Break

2:00 Human Papillomavirus (HPV) Vaccines

Introduction

Update on literature related to reduced number of doses for HPV vaccination

KEN SHE trial

HPV vaccination coverage

Modeling of reduced number of doses for HPV vaccination

Modified EtR: wording of the age for routine HPV vaccination

Workgroup next steps and considerations

Dr. Oliver Brooks (ACIP, WG Chair)
Dr. Carla DeSisto (CDC/NCIRD)
Dr. Ruanne Barnabas (Harvard University)
Ms. Cassandra Pingali (CDC/NCIRD)
Dr. Jane Kim (Harvard University)
Dr. Ruth Stefanos (CDC/NCIRD)
Dr. Lauri Markowitz (CDC/NCIRD)

4:00 Cytomegalovirus (CMV) Vaccines

Introduction

CMV and cCMV epidemiology and disease burden

CMV vaccine safety and immunogenicity data

Initial workgroup considerations for CMV vaccine policy

Dr. Denise Jamieson (ACIP, WG Chair)
Dr. Tatiana Lanzieri (CDC/NCIRD)
Dr. Robert Paris (Moderna)
Dr. Tatiana Lanzieri (CDC/NCIRD)
Dr. David Sugerman (CDC/NCIRD)

5:00 U.S. Measles Update

5:30 Adjourn

Final Agenda

Wednesday, April 16, 2025

8:00 Welcome & Introductions

8:15 Meningococcal Vaccines

Introduction

GSK pentavalent vaccine: update of EtR and workgroup considerations

Updates to Meningococcal vaccines VFC resolution

Introduction to MenQuadfi label change for infants

MenQuadfi in infants: safety and immunogenicity

Workgroup considerations regarding MenQuadfi in infants

9:30

Break

9:45 Respiratory Syncytial Virus (RSV) Vaccines - Adults

Introduction

Manufacturer Presentation: mRNA-1345 (Moderna) Immunogenicity in Adults 18-59 at Increased Risk; 24-Month Re-Vaccination

Manufacturer Presentation: Arexvy (GSK) 36-Month Re-Vaccination

Economic Analysis of Adult RSV Vaccination, including benefits and risk discussion

Comparison of Economic Analyses of Adult RSV Vaccination

Evidence to Recommendations

Clinical Considerations

12:15

Break

12:30 Chikungunya Vaccines

Introduction

EtR for use of virus-like particle chikungunya vaccine among adolescent and adult travelers

EtR for use of virus-like particle chikungunya vaccine among laboratory workers

Surveillance for adverse events following use of live attenuated chikungunya vaccine and its use among travelers

Clinical guidance for use of virus-like particle chikungunya vaccine among pregnant and breastfeeding women

3:00

Break

3:10 Public Comment

3:40 VOTES

Meningococcal Vaccines

Meningococcal Vaccines VFC

RSV Adult

Chikungunya Vaccines

4:10 Respiratory Syncytial Virus (RSV) Immunizations- Maternal/Pediatric

Introduction

EtR: Clesrovimab

Clinical considerations

5:10 Adjourn

Dr. Keipp Talbot (ACIP Chair)

Dr. Jamie Loehr (ACIP, WG Chair)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Rachel Dawson (Sanofi)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Albert Shaw (ACIP, WG Chair)

Dr. Frances Priddy (Moderna)

Dr. Susan Gerber (GSK)

Dr. Ismael Ortega-Sanchez (CDC/NCIRD)

Dr. Ismael Ortega-Sanchez (CDC/NCIRD)

Dr. Diya Surie (CDC/NCIRD), Dr. Michael Melgar (CDC/NCIRD)

Dr. Diya Surie (CDC/NCIRD)

Dr. Edwin Asturias (ACIP/WG Chair)

Dr. Susan Hills (CDC/NCEZID)

Dr. Erin Staples (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID),

Dr. Erin Staples (CDC/NCEZID)

Dr. Susan Hills (CDC/NCEZID), Dr. Dana Meaney-Delman (CDC/NCBDDD)

Dr. Sarah Schillie (CDC/NCIRD)

Dr. Jeanne Santoli (CDC/NCIRD)

Dr. Michael Melgar (CDC/NCIRD)

Dr. Susan Hills (CDC/NCEZID)

Dr. Helen Chu (ACIP, WG Chair)

Ms. Danielle Moulia (CDC/NCIRD)

Dr. Jefferson Jones (CDC/NCIRD)

Final Agenda

Acronyms

cCMV	Congenital cytomegalovirus
CDC	Centers for Disease Control and Prevention
CMV	Cytomegalovirus
COVID-19	Coronavirus disease 2019
DPH	Department of Public Health
EtR	Evidence to Recommendations Framework
HPV	Human papillomavirus
NCBDDD	National Center on Birth Defects and Developmental Disabilities
NCIRD	National Center for Immunization & Respiratory Diseases
NCEZID	National Center for Emerging and Zoonotic Diseases
PHIC	Public Health Infrastructure Center
RSV	Respiratory Syncytial Virus
WG	Work Group
VFC	Vaccines for Children